Sugi Predict

Sugi Predict / Compounds / SCHEMBL7034026

SCHEMBL7034026

SCHEMBL7034026

CC(C)(C)c1nc2cc([N+](=O)[O-])ccc2[nH]1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.78
▸ SMN1; SMN2 Q16637 2/20 0.78
▸ L3MBTL1 Q9Y468 1/20 0.78
▸ NPBWR1 P48145 3/20 0.50
▸ CSNK1D P48730 1/20 0.47
▸ CSNK1G2 P78368 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ MAPT P10636 7/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ POLB P06746 2/20 0.45
▸ MAOB P27338 1/20 0.45
▸ NOS1 P29475 1/20 0.45
▸ GRIA1 P42261 1/20 0.45
▸ GRIA2 P42262 1/20 0.45
▸ GRIA3 P42263 1/20 0.45
▸ GRIA4 P48058 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7034030 0.88 SMN1; SMN2 (1.00) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1CSNK1D
SCHEMBL13543998 0.86 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1CSNK1D
SCHEMBL18537878 0.85 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1
SCHEMBL5423878 0.85 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1
SCHEMBL8371791 0.84 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1CSNK1D
SCHEMBL18776091 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1CSNK1D
SCHEMBL4328210 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1
SCHEMBL18757839 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1
SCHEMBL7210029 0.78 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1
SCHEMBL2711226 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1NPBWR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552770-B2 Compounds for treating respiratory disease TMEM16A LIMITED (GB) 2026-02-17 — — US disclosed
WO-2025137303-A1 META-PHENYLENEDIAMINE ANTIDEGRADANT COMPOUNDS AND USES THEREOF FLEXSYS AMERICA L.P. (US) 2025-06-26 — — WO disclosed
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM16A LTD (GB) 2022-03-31 — — US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 — — US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 — — US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20030181730-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2003-09-25 — — US disclosed
US-20030022927-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2003-01-30 — — US disclosed
US-6495583-B1 DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN SYNAPTIC PHARMACEUTICAL CORPORATION 2002-12-17 — — US disclosed
US-6436982-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-08-20 — — US disclosed
US-20020072536-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-13 — — US disclosed
US-6403626-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-11 — — US disclosed
US-20020065307-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-05-30 — — US disclosed
US-6316637-B1 SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-11-13 — — US disclosed
EP-0775134-A4 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMA CORP (US) 1997-08-13 — — EP disclosed
EP-0775134-A1 Imidazolin-2-ylaminobenzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-05-28 — — EP disclosed
WO-1996004270-A1 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552770-B2 Compounds for treating respiratory disease TMEM109, SCN1A, SLC16A1 ALDH1A1 596/4885SMN1; SMN2 454/4885L3MBTL1 1760/4885
US-20020065307-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 ALDH1A1 938/4885SMN1; SMN2 2203/4885L3MBTL1 437/4885
US-20020072536-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 ALDH1A1 923/4885SMN1; SMN2 2392/4885L3MBTL1 414/4885
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 ALDH1A1 2353/4885SMN1; SMN2 4707/4885L3MBTL1 2178/4885
US-20030022927-A1 Novel benzimidazole derivatives OPRL1, OPRD1, OPRM1 ALDH1A1 1022/4885SMN1; SMN2 2343/4885L3MBTL1 351/4885
US-20030181730-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 ALDH1A1 938/4885SMN1; SMN2 2203/4885L3MBTL1 437/4885
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM109, SLC16A1, CFTR ALDH1A1 843/4885SMN1; SMN2 680/4885L3MBTL1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.